Scholar IQ
Try ScholarIQ free
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Intellia Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Intellia Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Intellia Therapeutics (United States)?

ScholarIQrecord summary

Intellia Therapeutics (United States) is a research organisation in Cambridge, United States. OpenAlex records 99 works and 48,910 citations for it. 1 researchers list it as their most recent affiliation.

How many works does Intellia Therapeutics (United States) have?

ScholarIQindexed works

Intellia Therapeutics (United States) has 99 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Intellia Therapeutics (United States) have?

ScholarIQcitation count

Intellia Therapeutics (United States) has 48,910 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Intellia Therapeutics (United States)?

ScholarIQresearcher count

Intellia Therapeutics (United States) has 1 researchers in the ScholarIQ index.

What is the average h-index at Intellia Therapeutics (United States)?

ScholarIQavg h-index

Intellia Therapeutics (United States) has an average h-index of 44 in OpenAlex.

What is the ROR of Intellia Therapeutics (United States)?

ScholarIQror

The ROR for Intellia Therapeutics (United States) is on the source record.

What is the OpenAlex record for Intellia Therapeutics (United States)?

ScholarIQopenalex

The OpenAlex for Intellia Therapeutics (United States) is on the source record.

Who are the most-cited researchers behind Intellia Therapeutics (United States)?

ScholarIQtop researchers by citations
1
David Lebwohl · Cancer Treatment and Pharmacology
90 works27,486 citations

What are the most-cited papers on Intellia Therapeutics (United States)?

ScholarIQmost cited works
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp
New England Journal of Medicine. 20185,720 CitationsOPEN ACCESS
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg
New England Journal of Medicine. 20112,863 CitationsOPEN ACCESS
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao
The Lancet. 20111,054 Citations
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Е. Д. Белоусова, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J. de Vries, Vicky Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde
The Lancet. 2013888 Citations
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann
Journal of Clinical Oncology. 2009650 CitationsOPEN ACCESS

How much of the research on Intellia Therapeutics (United States) is open access?

ScholarIQopen access share
60%OPEN ACCESS
Gold
0%
Green
20%
Hybrid
0%
Bronze
40%
Closed
40%
470M+ articles · free account